Back to main page

DREAM Module Identification Challenge – Consensus modules

PPI-STRING_Consensus_mod65

Assigned name NA Network PPI-STRING Module ID PPI-STRING_Consensus_mod65 Module size 43 genes

Module genes

This module comprises the following genes:

Gene ID Gene Symbol Gene Name 84320 ACBD6 acyl-CoA binding domain containing 6 348094 ANKDD1A ankyrin repeat and death domain containing 1A 728780 ANKDD1B ankyrin repeat and death domain containing 1B 255239 ANKK1 ankyrin repeat and kinase domain containing 1 57763 ANKRA2 ankyrin repeat family A member 2 27063 ANKRD1 ankyrin repeat domain 1 54522 ANKRD16 ankyrin repeat domain 16 26287 ANKRD2 ankyrin repeat domain 2 118932 ANKRD22 ankyrin repeat domain 22 200539 ANKRD23 ankyrin repeat domain 23 23243 ANKRD28 ankyrin repeat domain 28 147463 ANKRD29 ankyrin repeat domain 29 554226 ANKRD30BL ankyrin repeat domain 30B like 51239 ANKRD39 ankyrin repeat domain 39 91526 ANKRD44 ankyrin repeat domain 44 157567 ANKRD46 ankyrin repeat domain 46 54851 ANKRD49 ankyrin repeat domain 49 283373 ANKRD52 ankyrin repeat domain 52 129138 ANKRD54 ankyrin repeat domain 54 100310846 ANKRD61 ankyrin repeat domain 61 441869 ANKRD65 ankyrin repeat domain 65 56311 ANKRD7 ankyrin repeat domain 7 51665 ASB1 ankyrin repeat and SOCS box containing 1 136371 ASB10 ankyrin repeat and SOCS box containing 10 140456 ASB11 ankyrin repeat and SOCS box containing 11 142689 ASB12 ankyrin repeat and SOCS box containing 12 79754 ASB13 ankyrin repeat and SOCS box containing 13 142686 ASB14 ankyrin repeat and SOCS box containing 14 51130 ASB3 ankyrin repeat and SOCS box containing 3 51666 ASB4 ankyrin repeat and SOCS box containing 4 140458 ASB5 ankyrin repeat and SOCS box containing 5 140460 ASB7 ankyrin repeat and SOCS box containing 7 140461 ASB8 ankyrin repeat and SOCS box containing 8 140462 ASB9 ankyrin repeat and SOCS box containing 9 602 BCL3 B cell CLL/lymphoma 3 1031 CDKN2C cyclin dependent kinase inhibitor 2C 1032 CDKN2D cyclin dependent kinase inhibitor 2D 92565 FANK1 fibronectin type III and ankyrin repeat domains 1 2553 GABPB1 GA binding protein transcription factor subunit beta 1 84807 NFKBID NFKB inhibitor delta 26578 OSTF1 osteoclast stimulating factor 1 116729 PPP1R27 protein phosphatase 1 regulatory subunit 27 8625 RFXANK regulatory factor X associated ankyrin containing protein

Functional annotation

Modules were tested for enrichment in functional and pathway annotations using two complementary approaches:
1. To select a small number of specific / non-redundant annotations for each module, a regression-based approach was used;
2. To obtain the complete set of enriched annotations, an extension of Fisher’s exact test that takes annotation bias into account was employed (Wallenius’ non-central hypergeometric distribution).

Most specific annotations for this module

Coeff.1 P-value.2 Source.3 Term.4 Class.5 6.71e-02 1.56e-06 GO titin binding molecular_function 1.44e-02 1.30e-15 Reactome Neddylation Metabolism of proteins 1.35e-02 1.80e-04 GO cyclin-dependent protein serine/threonine kinase inhibitor activity molecular_function 3.11e-04 3.67e-14 Reactome Antigen processing: Ubiquitination & Proteasome degradation Immune System

¹Regression coefficient

²Fisher’s exact test nominal P-value

³Annotation source (Reactome, GO biological process (BP), molecular function (MF) and cellular component (CC))

⁴GO category or Reactome pathway

⁵High-level branch of annotation tree

Gene membership

All enriched annotations

Gene Ontology

P-value1 FDR2 Term 1.25e-07 6.95e-05 protein ubiquitination 2.09e-07 1.12e-04 protein modification by small protein conjugation 1.34e-06 4.16e-04 titin binding 3.07e-05 7.30e-03 ubiquitin protein ligase binding 3.27e-05 7.72e-03 ubiquitin-like protein ligase binding 1.01e-04 2.09e-02 histone deacetylase binding 2.61e-04 4.57e-02 myofibril 2.69e-04 4.91e-02 cyclin-dependent protein serine/threonine kinase inhibitor activity 3.14e-04 5.37e-02 contractile fiber 3.84e-04 6.43e-02 ubiquitin ligase complex 8.62e-04 1.35e-01 cyclin-dependent protein serine/threonine kinase regulator activity 9.40e-04 1.46e-01 protein serine/threonine kinase inhibitor activity 1.08e-03 2.10e-01 negative regulation of cytokine biosynthetic process 1.25e-03 1.87e-01 protein kinase regulator activity 1.32e-03 1.96e-01 transcription factor binding 1.47e-03 2.70e-01 skeletal muscle cell differentiation 1.59e-03 2.31e-01 kinase regulator activity 1.76e-03 2.36e-01 I band 1.95e-03 3.34e-01 positive regulation of thymocyte apoptotic process 1.95e-03 3.34e-01 positive regulation of T cell apoptotic process

¹1Nominal enrichment p-value (Wallenius’ noncentral hypergeometric distribution)

²FDR corrected p-value (Benjamini-Hochberg)

Reactome

P-value1 FDR2 Term 0.00e+00 0.00e+00 ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION 0.00e+00 0.00e+00 CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION 9.83e-09 2.16e-06 ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION 1.18e-08 2.57e-06 CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION 2.16e-05 3.88e-03 G1 PHASE 2.26e-05 4.04e-03 MITOTIC G1 G1 S PHASES 1.58e-03 1.51e-01 G1 PHASE 4.06e-03 3.85e-01 CELL CYCLE MITOTIC 7.69e-03 5.92e-01 MITOTIC G1 G1 S PHASES 8.76e-03 7.20e-01 CELL CYCLE

¹1Nominal enrichment p-value (Wallenius’ noncentral hypergeometric distribution)

²FDR corrected p-value (Benjamini-Hochberg)

Mouse mutant phenotypes

P-value1 FDR2 Term 3.27e-03 1e+00 abnormal apoptosis 3.76e-03 1e+00 abnormal Leydig cell differentiation 4.03e-03 1e+00 abnormal class switch recombination 5.48e-03 1e+00 decreased B cell proliferation 5.62e-03 1e+00 nonsyndromic hearing loss 5.62e-03 1e+00 abnormal dendritic cell number 5.63e-03 1e+00 abnormal pituitary intermediate lobe morphology 5.63e-03 1e+00 increased plasmacytoid dendritic cell number 5.63e-03 1e+00 abnormal spleen marginal zone macrophage morphology 5.64e-03 1e+00 abnormal lymph node medulla morphology 7.49e-03 1e+00 increased renal carcinoma incidence 7.49e-03 1e+00 abnormal blood pressure regulation 7.49e-03 1e+00 abnormal myeloid dendritic cell morphology 7.50e-03 1e+00 increased testis tumor incidence 7.51e-03 1e+00 pituitary gland hyperplasia 7.51e-03 1e+00 abnormal thymus size 9.35e-03 1e+00 abnormal cochlear hair cell physiology 9.37e-03 1e+00 abnormal metallophilic macrophage morphology 1.08e-02 1e+00 decreased interferon-gamma secretion 1.12e-02 1e+00 enlarged pituitary gland

¹1Nominal enrichment p-value (Wallenius’ noncentral hypergeometric distribution)

²FDR corrected p-value (Benjamini-Hochberg)